Abstract 2744: Identification of Synergistic Effect of Autophagy Inhibitors and Resveratrol on BRCA1 Mutant Cancer Cells

Guelaguetza Vazquez-Ortiz,Cristine L. Chisholm,Ruili Huang,Cuiling Li,Xiaoling Xu,Wang Rui-Hong,Chuxia Deng

DOI: https://doi.org/10.1158/1538-7445.am2012-2744

IF: 11.2

2012-01-01

Cancer Research

Abstract:Abstract Over 200,000 new breast cancer cases are diagnosed in the US each year, with 5% of cases caused by mutations in BRCA1 (Breast cancer associated gene 1). Mutation carries have a lifetime risk of up to 80% for developing breast cancer. Current treatment options are limited and often do not lead to cure. We showed previously that treatment with resveratrol, although initially reduced more the tumor size in BRCA1 mutant (mt) tumors, with respect to BRCA1 wild-type (wt) in mice, tumors continued to grow after prolonged treatment. To identify small molecules that can be repurposed and synergize the killing effect of resveratrol in BRCA1-mt tumors, we screened the NCGC Pharmaceutical Collection in which, more than 52% are drugs approved for human or animal use by FDA, and the rest are drugs approved in other countries or in clinical trial. Using a high-throughput cell viability assay by measuring intracellular ATP content, we identified the inhibitory effect of 43 compounds that exhibited synergy with resveratrol (Res) with efficacy>50% and potency <35uM. We further analyzed 4 of them, cantharidin, chloroquine, amodiaquin and colchicine for in vivo study. Utilizing BRCA1-mt breast tumor implant models in aythymic mice reveal that mice treated with combination therapy (Drug + Res) exhibit significantly reduced tumor volumes and increased survival rate compared with mice on monotreatment and this effect was even more significant when compared to wt-BRCA1. Also, some mammary tumors developed in the BRCA1 mammary tissue specific mutant mice exhibited a total regression with combination therapy. In order to identify a shared molecular and biochemical change which make BRCA1-mt cancer cells more susceptible to the combination treatment, we found that these compounds inhibit autophagy at different levels, targeting the mTOR/AKT pathway at different levels and/or inhibiting the fusion between the lysosome and the phagosome producing strong vacuolization in the cytoplasm during treatment, increasing LC3-II in a Beclin independent manner, followed by a faster induction of apoptosis on the BRCA mutant cells. This approach offers the potential to combat breast cancer cells and sensitize BRCA1 deficient cells to more effective treatments. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2744. doi:1538-7445.AM2012-2744